



**Amendments to the Claims**

1.(original) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



in which  $R^a$  is a group of formula (i)




wherein  $P^1$  is phenyl, naphthyl or heteroaryl;

$R^1$  is halogen,  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl,  $COC_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, hydroxy, hydroxy $C_{1-6}$ alkyl, nitro,  $CF_3$ , cyano,  $SR^6$ ,  $SOR^6$ ,  $SO_2R^6$ ,  $SO_2NR^6R^7$ ,  $CO_2R^6$ ,  $CONR^6R^7$ ,  $CONR^6R^7$ ,  $NR^6R^7$ ,  $NR^6CO_2R^7$ ,  $NR^6CONR^7R^8$ ,  $CR^6=NOR^7$  where  $R^6$ ,  $R^7$  and  $R^8$  are independently hydrogen or  $C_{1-6}$ alkyl;

$a$  is 0, 1, 2 or 3;

or  $R^a$  is a group of formula (ii)



wherein

$P^2$  is phenyl, naphthyl, heteroaryl or a 5 to 7 membered heterocyclic ring;

$P^3$  is phenyl, naphthyl or heteroaryl;

$A$  is a bond or oxygen, carbonyl,  $CH_2$  or  $NR^4$  where  $R^4$  is hydrogen or  $C_{1-6}$ alkyl;

R<sup>2</sup> is as defined above for R<sup>1</sup> in formula (i) or R<sup>2</sup> is heteroaryl optionally substituted by C<sub>1</sub>-6alkyl, halogen or COC<sub>1</sub>-6alkyl or is a 5 - 7 membered heterocyclic ring optionally substituted by oxo;

R<sup>3</sup> is halogen, C<sub>1</sub>-6alkyl, C<sub>3</sub>-6cycloalkyl, C<sub>1</sub>-6alkoxy, COC<sub>1</sub>-6alkyl, hydroxy, nitro, CF<sub>3</sub>, cyano, CO<sub>2</sub>R<sup>6</sup>, CONR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>R<sup>7</sup> where R<sup>6</sup> and R<sup>7</sup> are as defined above;

b and c are independently 0, 1, 2 or 3;

Y is a single bond, CH<sub>2</sub>, O or NR<sup>5</sup> where R<sup>5</sup> is hydrogen or C<sub>1</sub>-6alkyl;

W is -(CR<sup>9</sup>R<sup>10</sup>)<sub>t</sub>- where t is 2, 3 or 4 and R<sup>9</sup> and R<sup>10</sup> are independently hydrogen or C<sub>1</sub>-6alkyl or W is a group -CH=CH-;

R<sup>b</sup> is hydrogen, halogen, hydroxy, C<sub>1</sub>-6alkyl, CF<sub>3</sub>, COC<sub>1</sub>-6alkyl, cyano or C<sub>1</sub>-6alkoxy;

R<sup>c</sup> is hydrogen or C<sub>1</sub>-6alkyl;

R<sup>d</sup> and R<sup>e</sup> are independently C<sub>1</sub>-4alkyl.

2.(original) A compound according to claim 1 in which R<sup>a</sup> is a group of formula (i) wherein P<sup>1</sup> is phenyl.

3.(original) A compound according to claim 2 in which R<sup>1</sup> is halogen, C<sub>1</sub>-6alkyl, nitro, CF<sub>3</sub> or cyano.

4.(currently amended) A compound according to ~~any of the preceding claims~~ claim 1 in which Y is CH<sub>2</sub>.

5.(original) A compound according to claim 1 in which R<sup>a</sup> is a group of formula (ii) wherein A is a single bond, P<sup>3</sup> is phenyl or naphthyl and P<sup>2</sup> is phenyl, pyridyl, pyrazinyl, oxadiazolyl, oxazolyl or piperidinyl.

6.(currently amended) A compound according to ~~any of the preceding claim~~ claim 1 in which W is -CH<sub>2</sub>-CH<sub>2</sub>- or -CH=CH-.

7.(currently amended) A compound according to ~~any of the preceding claims~~ claim 1 in which R<sup>c</sup> is hydrogen or methyl.

8.(currently amended) A compound according to ~~any of the preceding claims~~ claim 1 in which R<sup>d</sup> and R<sup>e</sup> are both methyl.

9.(currently amended) A compound according to claim 1 which is ~~a compound E1-E73 (as described above)~~

*cis*-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[5-(6-methylpyridin-2-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[5-(2-methyloxazol-5-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-(2,3-dichlorobenzoyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[(3-nitrophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-6-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]-1,2,3,4-tetrahydro-7-(3,4,5-trimethylpiperazin-1-yl)quinoline,

*cis*-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2,3-dichlorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

*cis*-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2,3-difluorophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2,3-dichlorophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2,3-dichlorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(3-chloro-2-fluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2,3-difluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthylacetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-chloro-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[4-(2,6-dimethylpyridin-3-yl)-1-naphthoyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[4-(3,6-dimethylpyrazin-2-yl)-1-naphthoyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-chloro-3-fluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-bromo-3-fluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-bromo-3-chlorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-fluoro-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-fluoro-2-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-chloro-2-cyanophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-Acetyl-3-chlorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-bromo-2-methylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-cyano-2-methylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-bromo-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-Acetyl-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-methoxy-1-[(2-phenyl-3-(trifluoromethyl)pyrazol-4-ylcarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-6-(3,5-dimethylpiperazin-1-yl)-1-[4-(2,5-dimethylpyridin-4-yl)benzoyl]-5-methoxyindoline,

cis-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[2'-methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carbonyl]indoline,

cis-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[4-(2-methyl-6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)benzoyl]-indoline,

cis-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]indoline.

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-5-cyano-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

cis-1-[(3-aminocarbonyl-2-methylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

cis-5-methoxy-1-[4-(1-methylpiperidin-4-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline.)

cis-5-methoxy-1-[4-(piperidin-4-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indole.

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indole.

cis-1-(2,3-dichlorophenylaminocarbonyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indole.

cis-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthylacetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indole.

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindole.

cis-1-[(2,3-dichlorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindole.

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-fluoro-6-(3,4,5-trimethylpiperazin-1-yl)indole.

cis-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

cis-5-methoxy-1-[5-(6-methylpyridin-2-yl)-1-naphthylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

cis-5-methoxy-1-[5-(2-methyloxazol-5-yl)-1-naphthylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

cis-1-(2,3-dichlorophenylaminocarbonyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

cis-1-(3-chloro-2-fluorophenylaminocarbonyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

cis-1-[3-fluoro-2-(trifluoromethyl)phenylaminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

cis-1-[2-chloro-3-(trifluoromethyl)phenylaminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

cis-1-[2-chloro-3-methylphenylaminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline.

*cis*-1-[2-chloro-3-(trifluoromethyl)phenyl]aminocarbonyl]-5-methyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-(2,3-dichlorophenylaminocarbonyl)-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-(2,3-dichlorophenylaminocarbonyl)-5-chloro-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-(2,3-dichlorophenylaminocarbonyl)-5-bromo-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-(2,3-dichlorophenylaminocarbonyl)-5-ethyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[2-(trifluoromethyl)phenylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[2-fluoro-3-(trifluoromethyl)phenylaminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[2-chloro-3-(trifluoromethyl)phenylaminocarbonyl]-3,3-dimethyl-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2-chloro-3-trifluoromethyl)phenoxy]carbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

or a pharmaceutically acceptable salt thereof.

10.(original) A compound according to claim 1 which is

*cis*-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indole,

*cis*-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2,3-dichlorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline

*cis*-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[4-(2-methyl-6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)benzoyl]-indoline,

*cis*-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindole,


*cis*-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-fluoro-6-(3,4,5-trimethylpiperazin-1-yl)indole,

*cis*-1-[2-chloro-3-(trifluoromethyl)phenyl]aminocarbonyl]-5-methyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline

or a pharmaceutically acceptable salt thereof.


11.(original) A process for the preparation of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof which comprises:

(a) where Y is NH, coupling a compound of formula (II):



(II)


in which R<sup>a</sup> is as defined in formula (I) with a compound of formula (III):



(III)


in which W, R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup> and R<sup>e</sup> are as defined in formula (I); or

(b) where Y is NR<sup>5</sup>, reacting a compound of formula (IV)



in which R<sup>a</sup> and R<sup>5</sup> are as defined in formula (I) with a compound of formula (III) as defined above together with an appropriate urea forming agent; or

(c) where Y is a single bond, CH<sub>2</sub> or O, reacting a compound of formula (V)



in which R<sup>a</sup> is as defined in formula (I) and L is an appropriate leaving group, with a compound of formula (III) as defined above;

and optionally thereafter for process (a), (b) or (c):

- removing any protecting groups,
- converting a compound of formula (I) into another compound of formula (I),
- forming a pharmaceutically acceptable salt.

12.(currently amended) A compound according to ~~any one of claims 1 to 10~~ claim 1 for use in therapy.

13.(currently amended) A compound according to ~~any one of claims 1 to 10~~ claim 1 for use in the treatment of depression.

14.(currently amended) A pharmaceutical composition which comprises a compound according to ~~any one of claims 1 to 10~~ claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

15.(currently amended) A compound of formula (I) as defined in ~~any one of claims 1 to 10~~ claim 1 or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of diseases or disorders where an antagonist of the 5-HT<sub>1B</sub> receptor is beneficial.

16.(currently amended) The use of a compound of formula (I) as defined in ~~any one of claims 1 to 10~~ claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of diseases or disorders where an antagonist of the 5-HT<sub>1B</sub> receptor is beneficial.